As we look at the diagnostic trends of 2026, the demand for non-invasive testing is driving a surge in the use of surface markers for "liquid biopsies." By detecting specific antigens on circulating tumor cells (CTCs) found in the blood, clinicians can now monitor cancer progression without the need for painful and risky surgical biopsies. The Cell Surface Markers Market is playing a pivotal...

The Future of CNS Therapeutics: Innovation, AI, and Personalized Medicine CNS Therapeutics Market Overview 2025–2033 The Global Central Nervous System (CNS) Therapeutics Market is undergoing a significant transformation as neuroscience, biotechnology, and digital innovation converge to address complex neurological and psychiatric disorders. Valued at USD 123.7...

As of January 22, 2026, the Duchenne muscular dystrophy treatment market is identifying as one of the most high-value sectors in rare disease therapeutics, with its 2026 valuation reaching approximately $5.43 billion. The 2026 landscape is defined by a rapid CAGR of 17.1% to 29.4%, fueled by the aggressive commercialization of one-time gene therapies like Elevidys and the transition of...

Global Genomics Market Size, Share, Industry Analysis & Forecast 2033 Introduction The Global Genomics Market is expanding rapidly as advancements in sequencing technologies and bioinformatics continue to transform modern healthcare and life sciences research. Genomics involves the study of genes and their functions, enabling scientists and healthcare professionals to better...

In 2026, the one-size-fits-all approach to recovery is being replaced by highly personalized precision medicine. A major trend in the addiction treatment market is the use of genetic testing to understand how a patient’s unique DNA influences their response to specific medications like buprenorphine or naltrexone. By identifying genetic markers that affect metabolism and reward-seeking...

As of January 22, 2026, the PD-L1 inhibitors market is identifying as a powerhouse of modern oncology, with its 2026 valuation reaching approximately $57.5 billion within the broader $70.8 billion PD-1/PD-L1 checkpoint inhibitor landscape. The 2026 landscape is defined by a high-velocity CAGR of 13.88% to 19.85%, spurred by the aggressive expansion of drug labels into early-stage "adjuvant"...